Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
about
Synthetic lethality: emerging targets and opportunities in melanoma.New Horizons for Precision Medicine in Biliary Tract Cancers.Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Emerging molecular therapeutic targets for cholangiocarcinoma.Current biologics for treatment of biliary tract cancers.Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysCholangiocarcinoma - evolving concepts and therapeutic strategies.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.Wild-type and mutated IDH1/2 enzymes and therapy responses.Molecular genomic landscapes of hepatobiliary cancer.Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylationThe HER3 pathway as a potential target for inhibition in patients with biliary tract cancersIsocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
P2860
Q54808710-340C245A-12FD-4C4D-93C0-554193C687FBQ54808718-F6875E0E-1BFB-4539-BE3A-400C6FF6BC87Q54832088-C6FC77A1-64DF-485A-937B-B52FF19C7F84Q54835351-CD385B83-A1A5-4568-BAA1-D4F085039DD1Q54889772-B58BD867-7BC3-4FB0-9CAE-215FA05621B5Q54896725-2A9872E9-C550-42B8-8C15-1549DBF8FC8CQ54896845-53850E7C-DDD0-4F95-9C76-9CCE7D762EFDQ54906231-19A05A32-00C8-4766-A615-38092436C158Q94313309-DA989E39-4910-4778-A8F1-CE764776AB9DQ94313313-990F9BFF-CA02-431C-91F9-55A93E43E739Q94313317-38EE6014-80F6-4EE5-BD39-4742B678397E
P1343
Q33578398-CFF3EC25-715D-4E27-9DBD-10C2D2583579Q38619219-42C5E7C0-8296-4313-98BA-C4231AF88358Q38698657-5806A7A5-7480-4A15-8731-9E435884BDACQ38792334-21D2A2B7-C648-422A-B355-DCF71C3627FEQ39227356-AD281A95-2FDC-48B7-8920-8B064908161CQ39453572-3EFE1908-D233-4EFE-8D8E-765E6EF35C46Q40172727-557B6217-6300-4AC1-9109-60106FB3437DQ42371843-D93193B5-D5BB-450B-9716-83A67B319ABCQ46087686-8FDBDDD6-22D7-4421-954C-CB84230946CFQ47429093-37983061-1D12-47CA-98E2-350184B0CC43Q47713415-65E36A69-8823-4A50-96E0-1B5AA4A8CE35Q52343716-8C999CE3-4D76-4FA1-BDB0-62971BD23DDAQ55260649-5DA3DB4A-EA25-4F41-88EF-A58096B05B7DQ57112122-547CB29D-56ED-4943-8CB4-E206535D8235Q58601441-58A4478D-E50F-49CB-8EBA-1E56426F020AQ58728288-4347B6E1-E58D-4481-8EE9-6737981B05C3
P2860
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@ast
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@en
type
label
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@ast
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@en
prefLabel
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@ast
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@en
P2093
P2860
P50
P1433
P1476
Isocitrate Dehydrogenase Mutat ...... ntrahepatic Cholangiocarcinoma
@en
P2093
Andrew S Liss
Andrew X Zhu
Aram F Hezel
Cristina R Ferrone
Cyril H Benes
J Keith Joung
Jia-Chi Yeo
John D Gordan
Kevan M Shokat
Kimberly M Rieger-Christ
P2860
P304
P356
10.1158/2159-8290.CD-15-1442
P50
P577
2016-05-26T00:00:00Z